Assessment of ovarian tumor marker CA-125 during radiotherapy course

Year 2013, Volume: 30 Issue: 2, 137 - 139, 31.07.2013

Mohammed Alıomer , Mohamed Mohamed Mohamed Yousef , Mohammed Farahna Adel Alghanım

https://doi.org/10.5835/jecm.omu.30.02.010

https://izlik.org/JA33ED36AM

Abstract

The antigen secretion by ovarian cancer (CA-125) has been assessed using Radio Immune Assay (RIA) technique among a hundred ovarian cancer patients who received radiotherapy course as radical treatment. The study revealed that, the ovarian cancer commonly associated with the age groups of 30-40 years old taking a percent of 68 relative to other age groups and the antigen CA-125 does not has relation with aging. While the radiotherapy shows it is efficiency in management of ovarian cancer by reducing the antigen CA-125 level from 134 ± 13.3 U/ml to 5.5 ± 2.1 U/ml relative to normal level of CA-125 (35 U/ml). Also there is significant relationship between the
cancer stage and the level of antigen CA-125 (R2=0.98).

Keywords

Ovarian cancer , Radiation therapy and tumor maker , Radioimmuneassay

References

• ACOG: American College of Obstetricians and Gynecologists, 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Obstet. Gynecol. 100, 1413-1416.
• American Cancer Society. Cancer Facts and Figures. (2012). Atlanta, GA.
• Bast, R.C. Jr., Feeney, M., Lazarus, M., Nadler, L.M., Colvin, R.B., Knapp, R.C., 1981. Reactivity of a monoclonal antibody with human ovarian carcinoma. J. Clin. Invest. 68, 1331-1337.
• Bast, R.C. Jr., Klug, T.L., ST. John, E., 1983. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med., 308, 883-887.
• Bhattacharya, M., Chatterjee, S.K., Barlow, J.J., Fuji, H. 1982. Monoclonal antibodies recognizing Tumour-associated antigens of human ovar- ian mucinous cystadenocarcinomas. Cancer Res. 42, 1650-1654.
• Canney, P.A., Moore M., Wilkinson, P.M., James, R.D., 1984. Ovarian cancer antigen CA125: A prospective clinical assessment of its role as a tumor marker. Brth. J. Cancer. 50, 765-769.
• Coussy, F., Chéreau, E., Daraï, E., Dhombres, F., Lotz, J.P., Rouzier, R., Selle, F., 2011. Interest of CA 125 level in management of ovarian can- cer. Gynecol. Obstet. Fertil. 39, 296-301.
• Donaldson, E.S., Van Nagell, J.R., Pursell, S., 1980. Multiple biochemical markers on patients with gynaecologic malignancies. Cancer. 45, 948-953.
• Goone Wardene, T.I., 2007. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncol. 8, 813-821.
• Gregory, P. Beehler., Manveen S., Julie, A. B., Barbara E. T., Susan, E. M., Kerry J. R., and Kirsten B. M., 2006. Risk of ovarian cancer associ- ated with BMI varies by menopausal status.J. Nutr. 136, 2881–2886.
• Hogdall, E., 2008. Cancer antigen CA-125 and prognosis. Curr. Opin. Obstet. Gynecol. 20, 4-8.
• Keys, A., Fidanza, F., Karvonen, M.J., Kimura, N., Taylor, H.L., 1972. Indices of relative weight and adiposity. J. Chronic. Dis. 25, 329-343.
• Kramer, J.L., Greene, M.H., 2004. Epidemiology of Ovarian, Fallopian Tube, and Primary Peritoneal Cancers. in: Gynecologic Cancer: Contro- versies in Management. Gershenson, D., Gore, M., McGuire, W., Quinn, M., Thomas, G., editors. Elsevier Science. pp. 327-340.
• Manolov, V., Marinov, B., Vasilev, V., 2012. HE4 and CA125 in ovarian cancer. Akush. Ginekol. 51, 21-28.
• NCCN: National Comprehensive Cancer Network, 2009. NCCN Practice Guidelines in Oncology: Ovarian cancer, Vol. 2.
• Rustin, G.J.S., Nelstrop, A.E., Bentzen, S.M., Piccart, M.J., Bertelsen, K., 1999. Use of tumour markers in monitoring the course of ovarian cancer. Ann. Oncology. 10, 21-27.
• Rustin, G.J.S., Nelstrop, A.E., Tuxen, M.K, Lambert, H.E., 1996. Defining progression of ovarian carcinoma during follow-up according to CA-125: A North Thames Ovary Group Study. Ann. Oncology. 7, 361-364.
• Sproston, A.R.M., Roberts, S.A., Davidson, S.E., Hunter, R.D. , West, C.M.L., 1995. Serum tumor markers in carcinoma of the uterine cervix and outcome following radiotherapy. Brith. J. Cancer. 72,1536-1540.
• Tietz, N.W. (Ed)., 1995. Clinical guide to laboratory tests, 3rd. ed. W. B. Saunders, Philadelphia, PA .pp.
• Yin, B.W., Lloyd, K.O., 2001. Molecular cloning of the CA125 ovarian cancer antigen: Identification as a new mucin, MUC16. J. Biol. Chem. 276, 27371-27375. Ali Omer et al.